Use of drug-eluting balloon coronary intervention prior to living donor kidney transplantation
1 Department of Anesthesiology, University of Munich, Großhadern, Marchioninistrasse 15, 81377 Munich, Germany
2 Department of Thoracic and Cardiovascular Surgery, University Hospital, JW Goethe-University, Theodor–Stern–Kai 7, 61590 Frankfurt, Germany
3 Department of Surgery, University of Munich, Großhadern, Marchioninistrasse 15, 81377 Munich, Germany
4 Department of Cardiology, University of Munich, Großhadern, Marchioninistrasse 15, 81377 Munich, Germany
5 Department of Anaesthesiology – Clinic Fürstenfeldbruck, Dachauer Strasse 33, Fürstenfeldbruck D-82256, Germany
BMC Cardiovascular Disorders 2014, 14:112 doi:10.1186/1471-2261-14-112Published: 1 September 2014
Kidney transplantation is the gold standard of therapy in patients with terminal renal insufficiency. Living donor transplantation is a well-established option in this field. Enlarging the donor’s pool implicates the acceptance of an increased rate of comorbidities. Among them, coronary artery disease is a growing problem. An increasing number of patients, undergoing living donation, receive antiplatelet therapies due to coronary disease.
Here we report about the perioperative treatment with a drug-eluting balloon in a patient with major cardiac risk factors who underwent kidney transplantation.
At the current time no recommendation can be given for the routine use of drug-eluting balloons.